We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Agena Bioscience

Agena Bioscience® empowers research laboratories worldwide to deliver scalable targeted genomic data. Our advanced pl... read more Featured Products: More products

Download Mobile App




ctDNA Blood Tests Improve Lung Cancer Diagnosis

By LabMedica International staff writers
Posted on 11 Jun 2025

Lung cancer remains a major global health burden, being both the most frequently diagnosed cancer and the leading cause of cancer-related mortality worldwide. More...

When it spreads to other parts of the body, comprehensive molecular profiling of the tumor becomes essential to ensure patients receive the most suitable treatments. At present, treatment decisions are based on tumor tissue analysis, while radiological imaging is used to monitor treatment response. However, tumor samples are often insufficient or unavailable for such diagnostics, and imaging methods are frequently too insensitive to assess how well treatments are working reliably. These limitations can result in suboptimal care. When cells die, they release DNA into the bloodstream; in cancer, this includes circulating tumor DNA (ctDNA), which offers a potential alternative for diagnosis and monitoring. Despite its promise, there are still uncertainties about how ctDNA testing should be integrated into clinical practice. A new study has now explored key aspects that affect the clinical use of ctDNA testing in advanced non-small cell lung cancer (NSCLC).

In this study, researchers at University Medical Center Groningen (UMCG, Groningen, Netherlands) carried out a retrospective analysis of serially collected plasma samples from NSCLC patients at the time of diagnosis. Their goal was to assess how ctDNA testing could add value in detecting mutations with treatment relevance and what the clinical implications might be. The study analyzed 180 plasma samples from consecutively recruited NSCLC patients. Circulating cell-free DNA (ccfDNA) was extracted and evaluated using the UltraSEEK Lung Panel v2 on the MassARRAY System by Agena Bioscience (San Diego, CA, USA). For 132 patients, next-generation sequencing (NGS) data from tumor tissue, part of standard clinical molecular testing, were obtained from the national pathology registry.

The findings, published in the journal Nature, reveal that 82% of patients had concordant mutation findings between tumor tissue and plasma. Tumor tissue-based NGS identified more mutations in 19 patients, while plasma testing revealed additional mutations in four. Overall, tumor tissue profiling showed 60 patients were eligible for targeted therapies, including 15 (8%) with fusion mutations not detectable by the UltraSEEK panel. Using ctDNA analysis alone, 41 patients (23%) were identified as candidates for BRAFV600-, EGFR-, or KRASG12C-targeted treatments. Notably, in 48 cases where tumor tissue NGS was not available, ctDNA testing still detected five actionable mutations. These results indicate that ctDNA profiling can detect clinically relevant mutations at a rate comparable to traditional tissue-based NGS and could serve as either an alternative or a complementary method for identifying actionable genetic changes in plasma.

Related Links:
UMCG
Agena Bioscience


Gold Member
Troponin T QC
Troponin T Quality Control
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Staining Management Software
DakoLink
New
Clostridium Difficile Toxin A+B Combo Card Test
CerTest Clostridium Difficile Toxin A+B
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: How the predictive test works (Photo courtesy of QMUL)

World’s First Clinical Test Predicts Best Rheumatoid Arthritis Treatment

Rheumatoid arthritis (RA) is a chronic condition affecting 1 in 100 people in the UK today, causing the immune system to attack its joints. Unlike osteoarthritis, which is caused by wear and tear, RA can... Read more

Pathology

view channel
Image: A tool uses artificial intelligence and high-resolution imaging to track senescent cells (Courtesy of Adobe Stock)

AI-Assisted Technique Tracks Cells Damaged from Injury, Aging and Disease

Senescent cells, which stop growing and reproducing due to injury, aging, or disease, play a critical role in wound repair and aging-related diseases like cancer and heart disease. These cells, however,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.